Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease

K Poesen, M De Schaepdryver, B Stubendorff, B Gille… - Neurology, 2017 - AAN Enterprises
Objective: To determine the diagnostic performance and prognostic value of phosphorylated
neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) in CSF as possible …

Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis

M De Schaepdryver, A Jeromin, B Gille… - Journal of Neurology …, 2018 - jnnp.bmj.com
Objective Phosphorylated neurofilament heavy chain (pNfH) levels are elevated in
cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS). Instead of …

Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?

B Gille, M De Schaepdryver, L Dedeene… - Journal of Neurology …, 2019 - jnnp.bmj.com
Objective Inflammation is a key pathological hallmark in amyotrophic lateral sclerosis (ALS),
which seems to be linked to the disease progression. It is not clear what the added …

[HTML][HTML] Comparison of ELISA-and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis

S De Meyer, JM Schaeverbeke, IMW Verberk… - Alzheimer's research & …, 2020 - Springer
Background Blood-based amyloid biomarkers may provide a non-invasive, cost-effective
and scalable manner for detecting cerebral amyloidosis in early disease stages. Methods In …

Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults

J Schaeverbeke, B Gille, K Adamczuk… - Journal of …, 2019 - Wiley Online Library
The main pathophysiological alterations of Alzheimer's disease (AD) include loss of
neuronal and synaptic integrity, amyloidogenic processing, and neuroinflammation. Similar …

Automation on an open-access platform of Alzheimer's disease biomarker immunoassays

B Gille, L Dedeene, E Stoops… - SLAS …, 2018 - journals.sagepub.com
The lack of (inter-) laboratory standardization has hampered the application of universal
cutoff values for Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers and their …

Negative commercial screening test for paraneoplastic antibodies in a case of opsoclonus

N Vandenbussche, C Cassiman… - Neurology …, 2017 - AAN Enterprises
The diagnosis of a paraneoplastic syndrome (PNS) is challenging as it comprises a group of
clinically heterogeneous entities, all related to a coexistent, but sometimes occult …

Comparison of two analytical platforms for blood‐based surrogate biomarkers of amyloid pathology: Biomarkers (non‐neuroimaging)/plasma/serum/urine biomarkers

S De Meyer, J Schaeverbeke, B Gille… - Alzheimer's & …, 2020 - Wiley Online Library
Background Formation of amyloid plaques and fibrillary tau tangles in brain are key
pathological hallmarks in Alzheimer's disease (AD). Surrogate biomarkers of these …

[CITATION][C] P1‐200: Improvement of Reproducibility for CSF Biomarker Analysis by Integration of Automation in the Test Procedures

K Poesen, L Dedeene, B Gille, E Stoops… - Alzheimer's & …, 2016 - Wiley Online Library
Background The integration of CSF biomarker analysis in clinical routine or its global use in
clinical trials is hampered in-part by the presence of different analyte concentrations in …

[CITATION][C] [O1–10–04]: SYNAPTIC MARKERS IN LIQUOR INVERSELY CORRELATE WITH GRAY MATTER VOLUME IN COGNITIVELY HEALTHY INDIVIDUALS

B Gille, J Schaeverbeke… - Alzheimer's & …, 2017 - Wiley Online Library
Background Pathophysiological changes in brain appear up to 15 years prior to symptom
onset of Alzheimer's disease (AD)(Bateman, N Engl J Med, 2012). Accurate in vivo …